Literature DB >> 22633691

Design, synthesis, and evaluation of indanone derivatives as acetylcholinesterase inhibitors and metal-chelating agents.

Fan-Chao Meng1, Fei Mao, Wen-Jun Shan, Fangfei Qin, Ling Huang, Xing-Shu Li.   

Abstract

A series of novel indanone derivatives was designed, synthesised and evaluated as potential agents for Alzheimer's disease. Among them, compound 6a, with a piperidine group linked to indone by a two-carbon spacer, exhibited the most potent inhibitor activity, with an IC(50) of 0.0018 μM for AChE; the inhibitory activity of this compound was 14-fold more potent than that of donepezil. Furthermore, these compounds also exhibited good metal-chelating ability.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22633691     DOI: 10.1016/j.bmcl.2012.04.029

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  12 in total

1.  Isolation and acetylcholinesterase inhibitory activity of asterric acid derivatives produced by Talaromyces aurantiacus FL15, an endophytic fungus from Huperzia serrata.

Authors:  Yiwen Xiao; Weizhong Liang; Zhibin Zhang; Jun Chang; Du Zhu
Journal:  3 Biotech       Date:  2022-02-05       Impact factor: 2.406

2.  Bright Side of Lignin Depolymerization: Toward New Platform Chemicals.

Authors:  Zhuohua Sun; Bálint Fridrich; Alessandra de Santi; Saravanakumar Elangovan; Katalin Barta
Journal:  Chem Rev       Date:  2018-01-16       Impact factor: 60.622

Review 3.  Chalcone and its analogs: Therapeutic and diagnostic applications in Alzheimer's disease.

Authors:  Pritam Thapa; Sunil P Upadhyay; William Z Suo; Vikas Singh; Prajwal Gurung; Eung Seok Lee; Ram Sharma; Mukut Sharma
Journal:  Bioorg Chem       Date:  2021-01-29       Impact factor: 5.307

Review 4.  Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer's disease.

Authors:  Natalia Guzior; Anna Wieckowska; Dawid Panek; Barbara Malawska
Journal:  Curr Med Chem       Date:  2015       Impact factor: 4.530

5.  Design, synthesis and docking study of novel coumarin ligands as potential selective acetylcholinesterase inhibitors.

Authors:  Fatih Sonmez; Belma Zengin Kurt; Isil Gazioglu; Livia Basile; Aydan Dag; Valentina Cappello; Tiziana Ginex; Mustafa Kucukislamoglu; Salvatore Guccione
Journal:  J Enzyme Inhib Med Chem       Date:  2017-12       Impact factor: 5.051

Review 6.  Advances in Multi-Functional Ligands and the Need for Metal-Related Pharmacology for the Management of Alzheimer Disease.

Authors:  Abha Sharma; Vidhu Pachauri; S J S Flora
Journal:  Front Pharmacol       Date:  2018-11-15       Impact factor: 5.810

Review 7.  Profiling donepezil template into multipotent hybrids with antioxidant properties.

Authors:  Eva Mezeiova; Katarina Spilovska; Eugenie Nepovimova; Lukas Gorecki; Ondrej Soukup; Rafael Dolezal; David Malinak; Jana Janockova; Daniel Jun; Kamil Kuca; Jan Korabecny
Journal:  J Enzyme Inhib Med Chem       Date:  2018-12       Impact factor: 5.051

Review 8.  Molecular docking studies of coumarin hybrids as potential acetylcholinesterase, butyrylcholinesterase, monoamine oxidase A/B and β-amyloid inhibitors for Alzheimer's disease.

Authors:  Samina Khan Yusufzai; Mohammad Shaheen Khan; Othman Sulaiman; Hasnah Osman; Dalily Nabilah Lamjin
Journal:  Chem Cent J       Date:  2018-12-04       Impact factor: 4.215

9.  Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer's Disease.

Authors:  Angel Agis-Torres; Monica Sölhuber; Maria Fernandez; J M Sanchez-Montero
Journal:  Curr Neuropharmacol       Date:  2014-01       Impact factor: 7.363

10.  Phenoxyethyl Piperidine/Morpholine Derivatives as PAS and CAS Inhibitors of Cholinesterases: Insights for Future Drug Design.

Authors:  Yaghoub Pourshojaei; Ardavan Abiri; Khalil Eskandari; Zahra Haghighijoo; Najmeh Edraki; Ali Asadipour
Journal:  Sci Rep       Date:  2019-12-27       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.